This study examined the impact of disclosing subclassifications of genetic variants of uncertain significance (VUS) on behavioral intentions. We studied return of VUS results to 79 individuals with a cardiomyopathy-associated VUS, subclassified into VUS-high or VUS-low. Primary outcomes were perceived risk (absolute and comparative), perceived severity, perceived value of information, self-efficacy, decision regret, and behavioral intentions to share results and change behaviors. There was no significant difference between the 2 subclasses in overall behavioral intentions (t = 0.023, P = .982) and each of the individual items on the behavioral intentions scale; absolute (t = −1.138, P = .259) or comparative (t = −0.463, P = .645) risk perceptions; perceived value of information (t = 0.582, P = .563) and self-efficacy (t = −0.733, P = .466). 
classified as absolute in medicine or genetics. 3 The majority of results from NGS are interpreted as VUS, yet VUS results can have variable levels of evidence supporting pathogenicity. Some variants with pathogenicity evidence approach classification standards for "likely or definitely pathogenic," whereas others with no evidence of pathogenicity approach classifications for "likely or definitely benign."
The former may be described as a high VUS, VUS-high and the latter, low VUS, VUS-low.
Perceptions of uncertainty can affect individuals' decisions to learn, interpret, and act on sequencing results. 4 Although the negative impact of VUS results on recipients' risk perceptions, surgical decisions, and disease-specific distress 5 have been showed in breast cancer patients, there is limited evidence on how recipients respond to VUS results disclosure in other genetic diseases. Greater understanding of how participants perceive VUS and what they intend to do with them can help frame discussion of the benefits and harms associated with returning VUS results. 6 Although the ACMG/AMP system does not differentiate VUS results into subgroups 1 , if recipients interpret subclassifications of VUS results differently, it may be reasonable to use an expanded scoring system. One way to assess discrimination in perceptions is to explore whether division or subclassifications of VUS results into high and low groups leads to different outcomes. Accordingly, we conducted an experiment to test whether participants in a genome sequencing study who received VUS results divided into 1 of 2 subgroups (VUS-high and VUS-low) had different intentions to change their behaviors. The VUS results selected for this subclassification had no available published information in the literature and were divided into VUS-high and VUS-low subgroups based solely on a predictive algorithm score. How participants make cognitive, affective and behavioral distinctions among VUS results is largely unknown, but experimental results suggest that in the face of VUS results, research participants imbue them with meaning that may eventually have clinical consequences. 7, 8 Previous studies evaluating perceptions and treatment-related decisions following VUS disclosure are predominantly focused on BRCA1/2 genes. 9, 10 To our knowledge, there are no published studies on disclosure of VUS subclassification results and their impact on perceptions and behaviors. We aim to contribute to the literature on classification of uncertainties as they gain in complexity in the context of genome sequencing.
We used the Health Belief Model 11 (HBM) as a framework to examine the effect of disclosing the 2 VUS subclasses on recipients'
intentions to pursue health-related behaviors. The HBM hypothesizes that health-related actions depend on the occurrence of 4 factors: sufficient concern to make a health issue relevant (severity or seriousness); the belief that one is susceptible to a serious health concern (risk or susceptibility); and the belief that following a particular health recommendation would be beneficial in reducing the perceived threat (benefits); at a subjectively acceptable cost. There is well-established support for the role of self-efficacy in the initiation and maintenance of behavioral change. 12, 13 For a behavior change to succeed, people must believe themselves competent to implement that change.
A recent meta-analysis shows that experimental manipulations of risk perception have significant effects on health intentions (d = . 31) and behaviors (d = .23), 14 therefore, we included 2 well-validated assessments of risk perception that have been shown to be conceptually and empirically distinguishable from each other. The first is a measure of "absolute risk" or the subjective likelihood of succumbing to a cardiomyopathy, and the second measures the subjective likelihood of developing cardiomyopathy compared to a person with similar characteristics (comparative risk). To predict behavioral intentions, perceived risk (absolute and comparative), perceived severity, perceived benefit (information value) and self-efficacy were measured in VUS recipients.
Moreover, differences between the 2 VUS subgroups were assessed. Two of these items (intentions to change health behaviors and intentions to share results) have been used in previous publications. 7, 23 Each item was rated on a 5-point Likert scale from "1-definitely no"
| MATERIALS AND METHODS
to "5-definitely yes" following VUS disclosure.
Perceived risk was measured 2 ways using 2 distinct 1-item statements designed to assess absolute and comparative risks 23 to develop cardiomyopathy. A similar item has been used for nearly 15 years in the nationally representative Health Information National Trends Survey (HINTS; hints.cancer.gov) and has been shown to be predictive of many related constructs such as worry. 24 Participants rated how probable they were to get cardiomyopathy in their lifetime on a 7-point Likert scale from "1-extremely unlikely" to "7-extremely
likely." The second is a measure of comparative risk, which was included based on research showing that people often attend more to how their risk compares with that of similar others than they do to their absolute risk 25 . Participants were asked how their risk compared to that of others their same age and sex on a 7-point scale ranging
from "1-much less likely than the average person" to "7-much more likely than the average person." Comparative risk measures are often only moderately correlated with absolute risk measures, and in some studies, they explain additional (and sometimes more) variance in behavior relative to absolute risk perceptions. 26, 27 The single item measure of comparative risk used here has also been shown to be predictive of other related constructs, reliable over time and across contexts, 28 and distinguishable from the absolute risk measure. 24 Both of these measures have been used and validated in previous ClinSeq analyses. 23 Perceived severity was measured using a scale that was adapted from Champions' Perceived Severity Scale, a 12-item scale that measures the perceived impact an illness would have on respondents as well as the severity of the disease. Items are rated on a 5-item scale from "1-strongly disagree" to "5-strongly agree" with a Cronbach's α score of .78 and test-retest reliability of 0.76 across an interval of 2 weeks. Perceived self-efficacy predicts intention and behavior, reflecting a sense of control of one's environment and behavior 12 and was measured with responses to 2 questions: "I feel confident and competent to pursue health-related behaviors that could help manage and monitor my susceptibility to cardiomyopathy", and "I am certain my efforts to pursue health-related behaviors will be successful". Both questions were rated on a Likert scale of "1-very uncertain" to "5-very certain" with high internal consistency (Cronbach's α = .89).
The Decision Regret Scale (DRS) is a 5-item scale that measures regret associated with health care decisions. It is a well-validated scale with good internal consistency (Cronbach's α = .81-.92) and a strong correlation with decision satisfaction (r = −0.40 to −0.60) and decision conflict (0.31 to 0.52). 30 The DRS was added after 11 participants had completed their survey. The scale was modified to refer to regret associated with decision to learn VUS results (Cronbach's α = .89). The 5 items that make up the DRS are scored on a Likert scale from 1 (strongly agree) to 5 (strongly disagree). Items 2 and 4 were reverse-coded so that a higher number indicated more regret.
The mean score across items was computed and converted to a total score out of 100 with a score of 0 meaning no regret, scores between 0 and 30 interpreted as mild regret, and scores from 30 to 100 interpreted as moderate to high regret. 31 Participants were asked 3 open-ended questions to assess their understanding of VUS, if and how the result was shared with family members, and the ways in which they were satisfied and dissatisfied with the result disclosure process.
| Statistical analyses
Descriptive statistics were performed to characterize the demographics of the study sample. A series of t-tests was performed to investigate the effect of VUS subclassification (VUS-high and VUSlow) on perceived risk, perceived severity, perceived value of information, self-efficacy, decision regret, and behavioral intentions. Bivariate correlations were examined for variables predicted to explain behavioral intentions. Finally, combining both subclasses, the extent to which behavioral intentions could be considered a function of perceived risk, perceived severity, perceived value of information, self-efficacy, and sex was assessed through multiple linear regression analyses. All analyses for this study were accomplished using STATA 14 (StataCorp, College Station, Texas) and Microsoft Excel (Microsoft, Redmond, Washington). Statistical significance for all analyses was set at P < .05. Eighty percent of the participants in this study were white and had at least a college education. They ranged in age from 51 to 73 years and 48% were female (Table 1) . Prior to enrollment, 19% of study participants had a personal history of CAD (Bin 4). These demographic characteristics are consistent with those of larger samples of the ClinSeq population. 15 Of the 79 survey respondents, 33 were first-time ClinSeq result recipients and 46 had received genetic results from ClinSeq prior to participation in this project. Nine respondents reported a family history of cardiomyopathy (see Appendix S1). 
| Qualitative analyses

| VUS subclassification and behavioral intentions
Subclassification: VUS-L (low) and VUS-H (high).
a Average rating or sentiment among respondents. Calculated as follows: w 1 x 1 + w 2 x 2 + w 3 x 3 + ….w n x n /Total; w = weight assigned to each answer choice (superscript), and x = response count for answer choice. 
| VUS subclassification and risk perceptions
There were no differences in absolute (t = −1.138, P = .259) and comparative (t = −0.463, P = .645) risk perceptions, perceived severity (t = 0.675, P = .502), perceived information value (t = 0.582, P = .563), and self-efficacy (t = −0.733, P = .466) between the VUS subclasses.
Absolute risk perception was moderately correlated with comparative risk perception (r = 0.503, P < .001), irrespective of VUS subclass.
| VUS subclassification and decision regret
A total of 68 participants completed the DRS (Table 3) (t = 2.148, P = .035).
| Predictors of overall behavioral intentions
Combining both subclasses, perceived value of information was highly correlated with (r = 0.60, P < .001), and the strongest predictor 3.6 | Qualitative data
| VUS Meaning
Sixty-one individuals responded to the question "What do you understand your VUS to mean?" Most participants explained that it meant that the significance of the variant for their health was uncertain (n = 31) or made some reference to having a genetic "variant," a Average rating or sentiment among respondents. Calculated as follows: w 1 x 1 + w 2 x 2 + w 3 x 3 + ….w n x n /Total; w = weight assigned to each answer choice (in parenthesis), and x = response count for answer choice. 
COUNTS OF DECISION REGRET SCORES AND VUS SUB-CLASSIFICATION
VUS-Low (n=29) VUS-High (n=39) "change," or anomaly (n = 26). One participant stated, "In other words, a gene variant was found but there is no information to say if it is benign or harmful" (Male, 70, VUS-low). Thirteen participants (5 VUS-low, 8 VUS-high) used stronger language to describe the association of their variant and health risks, stating that the variant "may" or "could" put them at risk for a health condition without any qualifiers that the risk was unknown or uncertain at this time. There were no significant differences in overall behavioral intentions nor among the 4 items that make up the behavioral intentions scale (seek more information; share results with health care provider; change lifestyle/behavior; share results with family) between the 2 VUS subclasses. Thus, we cannot reject the null hypothesis that splitting VUS into VUS-high and VUS-low has no effect on health intentions. There were no significant differences in absolute and comparative risk perceptions, perceived severity, perceived information value, and self-efficacy between the VUS subclasses, which again does not allow us to reject the null hypothesis. There was a significant difference in decision regret, with regret being higher in those who received a VUS-low result (t = 2.148, P = .035). This result does provide some evidence that participants were able to recognize a VUS-low results and suggests that the perceived value of the result (independent of VUS-high or VUS-low) may be a stronger predictor of intentions than is VUS sub-classification.
| Sharing result with family members
Our qualitative data showed that participants had a good overall understanding of the meaning of a VUS by expressing nuance and sophistication regarding the results. There was a great degree of variation as to whether and if so, how the participants shared the result with family members. The qualitative responses on satisfaction of learning their result were also highly variable but did not obviously explain the association of VUS-high and VUS-low and decision regret that was noted above.
Our observation that satisfaction was more correlated with perceived value is of interest. This is consistent with our participants' self-reported positive attitudes and intentions toward receiving VUS results that were reported prior to joining this study and before they received any results. 32 Uncertainty resulting from lack of information about their variants was the most commonly reported source of dissatisfaction with these results, as would be expected.
Intention is the most proximal predictor of behavior. 33 In this sample, perceived benefit, operationalized as perceived value of information emerged as the only significant predictor of behavioral intentions (β = 0.530, P < .001). Similar to our findings, previous studies conducted to determine whether the dimensions of the HBM could longitudinally predict behavior showed that perceived benefits are stronger predictors of behavior than perceived risk and severity. 34 Limitations of this study include the fact that we collected data from a relatively small number of participants who were predomi- 
| CONCLUSION
There were no differences in behavioral intentions between the 2 cardiomyopathy-associated VUS subclasses. The difference in decision regret between VUS subclasses provides some support that recipients can distinguish VUS-high from VUS-low, but additional work is needed. Furthermore, a majority of VUS result recipients were satisfied with their experience and did not regret the decision despite the uncertainty associated with the disclosed information.
The perceived value of information was a strong positive predictor of participants' intentions to pursue health-related behaviors following disclosure of uncertain genetic information, irrespective of VUS subclass.
